Story should have cited real rea­sons for high drug prices

Modern Healthcare - - COMMENT -

Re­gard­ing “In­dus­try ad­mits lack of trans­parency spikes drug prices” (ModernHealth­care.com, May 17), why not men­tion the three most per­ni­cious causes of fail­ure to al­low mar­ket forces to work: the ex­cep­tion­ally long ex­clu­siv­ity a patented drug en­joys even if it was de­vel­oped with tax­payer money; the in­abil­ity of Medi­care to ne­go­ti­ate pric­ing with drug com­pa­nies (to me it would be rea­son­able to re­duce the length of a patent if the drug sells for more in the U.S. than it does out­side the coun­try); and, lastly, phar­macy ben­e­fit man­agers and their ridicu­lous tiered treat­ment requirements that rup­ture the doc­tor/ pa­tient re­la­tion­ship, as well as their in­ter­minable ap­peals pro­cesses.

When will Con­gress stop cod­dling Big Pharma, in­sur­ance com­pa­nies and other cam­paign donors?

Dr. Matthew L. Carr Fort Laud­erdale, Fla.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.